Nonmyeloablative Allogeneic Transplant



Status:Recruiting
Conditions:Breast Cancer, Skin Cancer, Ovarian Cancer, Cancer, Cancer, Blood Cancer, Lymphoma, Anemia, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - 72
Updated:4/2/2016
Start Date:October 2001
Contact:Carol Burian
Email:burian.carol@scrippshealth.org
Phone:858-554-2845

Use our guide to learn which trials are right for you!

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using Antithymocyte Globulin With Either Melphalan and Cladribine or Total Lymphoid Irradiation

Allogeneic transplant from a matched sibling for the treatment of a variety of illnesses
including bone marrow failure states, leukemias, myelodysplastic or myeloproliferative
syndromes, lymphoma, or myeloma using a nonmyeloablative preparative regimen.


Inclusion Criteria:

1. Age > 55 years or

2. Age < 55 and LVEF < 45% or creatinine clearance < 60 ml/min

3. Ability to cover the cost of the transplant, necessary medications, and
transportation/housing.

4. Caregiver must be available while outpatient

Guidelines for Cladribine-Melphalan-based conditioning:

- Bone Marrow Failure States Severe Aplastic Anemia (relapsed following
immunosuppressive therapy) Paroxysmal Nocturnal Hemoglobinuria (poor prognostic
features or hemosiderosis)

- AML (first CR except for t(15;17), inv16, t(8,21); second CR; relapse failing second
induction attempt)

- ALL (first CR with at least one poor prognostic feature; second or greater CR;
relapse failing reinduction attempt)

- MDS (RAEB, RAEBiT, CMMoL)

- CML (chronic phase; accelerated phase; blast phase following reinduction attempt; 2nd
chronic or accelerated phase following gleevec therapy

- Hodgkin's lymphoma (first or greater relapse)

- Non-Hodgkin's Lymphoma

- Aggressive Histology (includes T Cell NHL) Incomplete response to induction Second CR
Sensitive or refractory relapse

- Indolent Histology Second or greater relapse

- Mantle Cell Lymphoma (any Stage - must have received induction chemotherapy)

- Multiple Myeloma (10% residual plasmacytosis following anthracycline-based
chemotherapy or residual disease following autologous transplant)

- Waldenstrom Macroglobulinemia (must have failed either purine analogue-based
chemotherapy (Fludara or 2CdA) or standard CVP therapy; hyperviscosity or cytopenias)

Guidelines for total lymphoid irradiation-based conditioning

- MDS (RA, RARS)

- CLL (Rai stage III or IV - must have received at least two different treatment
regimens in the past)

- Breast Cancer (symptomatic metastatic disease, who have failed standard chemotherapy)

- Renal Cell Cancer (metastatic disease at multiple sites)

- Malignant Melanoma (metastatic disease at multiple sites)

- Sarcoma (all subtypes presently, unresectable metastatic disease)

- Ovarian Cancer (stage III or IV, platinum insensitive disease, i.e. progression
within 6 months of initial platinum chemotherapy)

- Thymoma (unresectable disease)

Exclusion Criteria:

1. Prior allogeneic stem cell or bone marrow transplant

2. Current or past history of invasive mycotic infection

3. Breast Feeding
We found this trial at
1
site
La Jolla, California 92037
?
mi
from
La Jolla, CA
Click here to add this to my saved trials